Pasithea Therapeutics (KTTA) Return on Sales (2022 - 2024)
Historic Return on Sales for Pasithea Therapeutics (KTTA) over the last 3 years, with Q1 2024 value amounting to 11.62%.
- Pasithea Therapeutics' Return on Sales fell 161800.0% to 11.62% in Q1 2024 from the same period last year, while for Mar 2024 it was 11.62%, marking a year-over-year decrease of 63000.0%. This contributed to the annual value of 4.54% for FY2022, which is 1397700.0% up from last year.
- Per Pasithea Therapeutics' latest filing, its Return on Sales stood at 11.62% for Q1 2024, which was down 161800.0% from 1.58% recorded in Q4 2023.
- In the past 5 years, Pasithea Therapeutics' Return on Sales registered a high of 4.56% during Q1 2023, and its lowest value of 34.5% during Q2 2022.
- For the 3-year period, Pasithea Therapeutics' Return on Sales averaged around 8.5%, with its median value being 2.84% (2023).
- Per our database at Business Quant, Pasithea Therapeutics' Return on Sales soared by 340200bps in 2023 and then tumbled by -161800bps in 2024.
- Quarter analysis of 3 years shows Pasithea Therapeutics' Return on Sales stood at 4.42% in 2022, then surged by 64bps to 1.58% in 2023, then tumbled by -638bps to 11.62% in 2024.
- Its Return on Sales stands at 11.62% for Q1 2024, versus 1.58% for Q4 2023 and 2.84% for Q3 2023.